Also trades as: 0UNL.L (LSE) · $vol 0M
NKTR NASDAQ
Nektar Therapeutics
1W: -3.2%
1M: -37.1%
3M: -46.3%
YTD: -12.6%
1Y: -36.8%
3Y: +390.6%
5Y: -84.8%
$37.97
+0.52 (+1.39%)
Pre-Market: $38.00 (+0.03, +0.07%)
Weekly Expected Move ±13.7%
$27
$32
$37
$42
$47
Credit Risk of going bust: higher than 66% of companies Debt: 11.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.56 (down 99%), Nektar Therapeutics would be worth roughly what it owes.
Total debt $135.9M against a stock market value of $1.09B.
Distance to default 3.74 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $51.4M (short-term plus half of long-term), stock volatility 79.7%; Altman Z'' -3.33. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.56 (down 99%), Nektar Therapeutics would be worth roughly what it owes.
Total debt $135.9M against a stock market value of $1.09B.
Distance to default 3.74 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $51.4M (short-term plus half of long-term), stock volatility 79.7%; Altman Z'' -3.33. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (24h)
1
Hourly Sentiment (24h)
Articles (1)
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Oppenheimer's top 50 small- and mid-cap Sell ideas
Quality trumps beta as 15-month cyclical rebound runs dry - strategist
Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?
Cedar Grove Capital Q3: Adds Zedcor, Auxly; exits MTY, ClearPoint
Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology
Nektar drops after new mid-stage trial data for hair loss drug
/UPDATE -- Nektar Therapeutics/
Nektar Therapeutics (NKTR) Climbs 2.20% to $60.55, Pressing Toward Upper Range - Chaikin Flow - siam.in
Nektar Therapeutics (NKTR) Unveils Promising Rezpegaldesleukin B - GuruFocus
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
How New Rezpegaldesleukin Durability and Mechanistic Data Could Impact Nektar Therapeutics (NKTR) Investors
What Could Nektar Therapeutics (NKTR) New Rezpegaldesleukin Data Mean For Its Case?
What Could Nektar Therapeutics (NKTR) New Rezpegaldesleukin Data Mean For Its Case? - finance.yahoo.com
How Investors May Respond To Nektar Therapeutics (NKTR) New Phase 2b Data Presentations - Simply Wall Street
Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026
After treatment stops, Nektar will present six-month data on severe hair loss - Stock Titan
Two funds hold 9.8% of Nektar Therapeutics (NKTR), with three parties reporting the same stake. - Stock Titan
Nektar Therapeutics (NKTR) Stock Dropped, So What Is Driving Attention Now? - Simply Wall Street
Nektar Therapeutics (NKTR) Dropped, So What Is Driving Attention Now?
Nektar Therapeutics (NKTR) Dropped, So What Is Driving Attention Now? - finance.yahoo.com
A Jury Awarded Nektar $90 Million From Eli Lilly. Here’s Why the Stock Barely Moved
Nektar Therapeutics (NKTR) grants a director 2,000 shares upon vesting and options to buy 4,000 more. - Stock Titan
A director receives 2,000 stock units alongside 4,000 options at Nektar Therapeutics (NKTR). - Stock Titan
Director Robert Chess also received 2,000 stock units from Nektar Therapeutics (NKTR), vesting in one year. - Stock Titan
Director Diana Brainard receives 2,000 stock units from Nektar Therapeutics (NKTR), vesting in one year. - Stock Titan
A director receives an option to buy 4,000 Nektar Therapeutics (NKTR) shares at $57.66 each. - Stock Titan
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 new hires got rights to buy 58,600 shares, plus 2,450 stock awards from Nektar. - Stock Titan
Sector Update: Healthcare Stocks Higher Late Afternoon
Sector Update: Healthcare Stocks Edge Higher in Afternoon Trading
Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case
Update: Nektar Wins $90 Million Jury Verdict Against Eli Lilly Over Rezpegaldesleukin Deal
Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury Funds
Nektar Therapeutics stock rises on $90M jury verdict vs Lilly - finance.yahoo.com
Nektar Therapeutics stock rises on $90M jury verdict vs Lilly
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
Sector Update: Healthcare Stocks Edge Higher Premarket Friday
Advanced AI-Powered Crypto Investment Research Platform - SoSoValue
Nektar gains 5% as jury awards $90M plus interest in Lilly trial
Nektar Therapeutics drops as jury deliberates in Eli Lilly patent dispute
Squarepoint Ops LLC Sells 101,578 Shares of Nektar Therapeutics $NKTR
HB Wealth Management LLC Purchases New Position in Nektar Therapeutics $NKTR
Bank of New York Mellon Corp Acquires Shares of 96,061 Nektar Therapeutics $NKTR
Nektar’s (NKTR) Billion-Dollar Balance Sheet Faces A Multi-Year Test
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Nektar (NKTR) Q2 2026 Earnings Call Transcript
Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus
Retail Sales Weaken in July
U.S. Stock Futures Mixed, Heads for a Winning Week
Nektar outlines REZPEG Phase III timeline with mid-2028 data and 2029 BLA plan
Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates
Nektar Therapeutics Announces Second Quarter 2026 Financial Results - PR Newswire
Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates
Earnings Week Ahead: SMCI, CSCO, JD, PLUG, and more
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Does Nektar (NKTR) Have the Potential to Rally 104.06% as Wall Street Analysts Expect?
NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitis
What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year
Russell 3000 Shuffle: Ocugen, Nektar slated to join among healthcare stocks; Nano-X to drop off
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares
Nektar Q1 Earnings & Revenues Lag Estimates, Pipeline in Focus
Nektar expects $800M-$825M cash at end of 2026 while targeting REZPEG BLA in 2029
Nektar (NKTR) Q1 2026 Earnings Transcript
Nektar Therapeutics Reports First Quarter 2026 Financial Results
Here are the major earnings after the close Thursday
Nektar Therapeutics Reports First Quarter 2026 Financial Results - PR Newswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers – NKTR
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
DEADLINE ALERT for EOSE, SLNO, and NKTR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Portnoy Law Firm Announces Class Action on Behalf of Nektar Therapeutics, Inc. Investors
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Enrollment Protocol Compliance: Levi & Korsinsky
NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm Before May 5th
NKTR DEADLINE NOTICE: ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTR
NKTR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTR
Lost Money With NKTR? Contact Glancy Prongay Wolke & Rotter LLP
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers – NKTR
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Aquestive Therapeutics, Inc. (AQST), Nektar Therapeutics (NKTR), and Eos Energy Enterprises, Inc. (EOSE) Announced by Holzer & Holzer, LLC
NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Inflating Trial Integrity Claims: Levi & Korsinsky
NKTR DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTR
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
DEADLINE ALERT for EOSE, SLNO, NKTR, DRVN: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a Securities Class Action Lawsuit Filed Against Nektar Therapeutics (NKTR)
Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PR Newswire
Nektar Therapeutics prices upsized $325M public offering at $92.00 per share
ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
Nektar (NKTR) Moves 18.3% Higher: Will This Strength Last?
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
Why Nektar Therapeutics Stock Rocked it Today
Nektar Therapeutics announces $250M public offering
Nektar Therapeutics, Compass Pathways, Sila Realty Trust And Other Big Stocks Moving Higher On Monday
Biggest stock movers Monday: Psychedelic stocks, BLD, USAR, and more
Why Are Nektar Shares Up Monday?
Nektar posts 52-week data from mid-stage trial for hair loss therapy
Nektar Therapeutics Announces Proposed Public Offering - PR Newswire
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
DEADLINE ALERT for BSX, EOSE, SLNO, and NKTR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Portnoy Law Firm Announces Class Action on Behalf of Nektar Therapeutics, Inc. Investors